Pulmatrix
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 22
- Market Cap
- $7.5M
- Website
- http://www.pulmatrix.com
A Safety and Tolerability Study OF PUR118 In Subjects With Cystic Fibrosis
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01543191
- Locations
- ๐ฌ๐ง
Celerion, Belfast, Northern Ireland, United Kingdom
Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118
- First Posted Date
- 2011-04-12
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT01333904
- Locations
- ๐ฌ๐ง
Quotient Bioresearch, Nottingham, United Kingdom
Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CALM) on Chronic Obstructive Pulmonary Disease (COPD) Sputum
Completed
- Conditions
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2011-04-11
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01096173
- Locations
- ๐บ๐ธ
VA WNY Healthcare System, Buffalo, New York, United States
Effect of PUR003 on Asthma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2011-11-22
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00989521
- Locations
- ๐จ๐ฆ
Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada
Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00947687
- Locations
- ๐ฌ๐ง
Guys Drug Research Unit (GDRU), Quintiles Ltd, London, United Kingdom
ยฉ Copyright 2024. All Rights Reserved by MedPath